FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
REDWOOD CITY, Calif., March 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 1, 2016, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 17,200 shares of the company’s common stock with a per share exercise price of $13.46, the closing trading price on the grant date, and 8,600 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
